Aberrant expression of glycogen synthase kinase‑3β in human breast and head and neck cancer

Ugolkov,Andrey  V.; Matsangou,Maria; Taxter,Timothy  J.; O'Halloran,Thomas  V.; Cryns,Vincent  L.; Giles,Francis  J.; Mazar,Andrew  P.

doi:10.3892/ol.2018.9483

Aberrant expression of glycogen synthase kinase‑3β in human breast and head and neck cancer

Authors:
- Andrey V. Ugolkov
- Maria Matsangou
- Timothy J. Taxter
- Thomas V. O'Halloran
- Vincent L. Cryns
- Francis J. Giles
- Andrew P. Mazar
View Affiliations

Affiliations: Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA, Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA, Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60208, USA, Department of Medicine, University of Wisconin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA
Published online on: September 21, 2018 https://doi.org/10.3892/ol.2018.9483
Pages: 6437-6444
Copyright: © Ugolkov et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glycogen Synthase Kinase‑3β (GSK‑3β), a serine/threonine protein kinase, has been implicated as a potential therapeutic target in human cancer. The objective of the present study was to evaluate aberrant expression of GSK‑3β as a potential biomarker in human breast and head and neck cancers. Nuclear/cytosolic fractionation, immunoblotting and immunohistochemical staining was used to study the expression of GSK‑3β in human breast and head and neck cancer. Aberrant nuclear accumulation of GSK‑3β in five human breast cancer cell lines was demonstrated and in 89/128 (70%) human breast carcinomas, whereas no detectable expression of GSK‑3β was found in benign breast tissue. Nuclear GSK‑3β expression was associated with HER‑2 positive tumors (P=0.02) and non‑triple negative breast carcinomas (P=0.0001), although nuclear GSK‑3β was observed in some samples across all breast cancer subtypes. Aberrant nuclear expression of GSK‑3β was found in 11/15 (73%) squamous cell head and neck carcinomas, whereas weak or no detectable expression of GSK‑3β was found in benign salivary gland and other benign head and neck tissues. These results support the hypothesis that aberrant nuclear GSK‑3β may represent a potential target for the clinical treatment of human breast and squamous cell carcinoma.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Argiris A, Karamouzis M, Raben D and Ferris R: Head and neck cancer. Lancet. 371:1695–1709. 2008. View Article : Google Scholar : PubMed/NCBI
3	Cohen P and Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol. 2:769–776. 2001. View Article : Google Scholar : PubMed/NCBI
4	Diehl JA, Cheng M, Roussel MF and Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12:3499–3511. 1998. View Article : Google Scholar : PubMed/NCBI
5	Rubinfeld B, Albert I, Porfir E, Fiol C, Munemitsu S and Polakis P: Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science. 272:1023–1026. 1996. View Article : Google Scholar : PubMed/NCBI
6	Sears R, Nuckolls F, Haura E, Taya Y, Tamai K and Nevins JR: Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14:2501–2514. 2000. View Article : Google Scholar : PubMed/NCBI
7	Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA and Billadeau DD: Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 65:2076–2081. 2005. View Article : Google Scholar : PubMed/NCBI
8	Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi M, Billadeau D, Mai M, Takahashi Y and Minamoto T: Deregulated GSK3beta activity in colorectal cancer: Its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 334:1365–1373. 2005. View Article : Google Scholar : PubMed/NCBI
9	Gaisina IN, Gallier F, Ougolkov AV, Kim KH, Kurome T, Guo S, Holzle D, Luchini DN, Blond SY, Billadeau DD and Kozikowski AP: From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 52:1853–1863. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST and Billadeau DD: Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: Association with kinase activity and tumor dedifferentiation. Clin Cancer Res. 12:5074–5081. 2006. View Article : Google Scholar : PubMed/NCBI
11	Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE and Billadeau DD: Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood. 110:735–742. 2007. View Article : Google Scholar : PubMed/NCBI
12	Bilim V, Ougolkov A, Yuuki K, Naito S, Kawazoe H, Muto A, Oya M, Billadeau D, Motoyama T and Tomita Y: Glycogen synthase kinase-3: A new therapeutic target in renal cell carcinoma. Br J Cancer. 101:2005–2014. 2009. View Article : Google Scholar : PubMed/NCBI
13	Naito S, Bilim V, Yuuki K, Ugolkov A, Motoyama T, Nagaoka A, Kato T and Tomita Y: Glycogen synthase kinase-3beta: A prognostic marker and a potential therapeutic target in human bladder cancer. Clin Cancer Res. 16:5124–5132. 2010. View Article : Google Scholar : PubMed/NCBI
14	Cao Q, Lu X and Feng Y: Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res. 16:671–677. 2006. View Article : Google Scholar : PubMed/NCBI
15	Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA and Chen H: Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther. 6:1151–1158. 2007. View Article : Google Scholar : PubMed/NCBI
16	Miyashita K, Kawakami K, Nakada M, Mai W, Shakoori A, Fujisawa H, Hayashi Y, Hamada J and Minamoto T: Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma. Clin Cancer Res. 15:887–897. 2009. View Article : Google Scholar : PubMed/NCBI
17	Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrashe JB and Li B: Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate. 71:835–845. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC and Cleary ML: Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature. 455:1205–1209. 2008. View Article : Google Scholar : PubMed/NCBI
19	Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O and Woodgett JR: Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 406:86–90. 2000. View Article : Google Scholar : PubMed/NCBI
20	Aggarwal BB: Nuclear factor-kappaB: The enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
21	Tas SW, Vervoordeldonk MJ and Tak PP: Gene therapy targeting nuclear factor-kappaB: Towards clinical application in inflammatory diseases and cancer. Curr Gene Ther. 9:160–170. 2009. View Article : Google Scholar : PubMed/NCBI
22	Medina M and Castro A: Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov Devel. 11:533–543. 2008.PubMed/NCBI
23	Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro BA, O'Halloran TV, Giles FJ, Billadeau DD and Mazar AP: Molecular pathways: Revisiting glycogen synthase kinase-3β as a target for the treatment of cancer. Clin Cancer Res. 23:1891–1897. 2017. View Article : Google Scholar : PubMed/NCBI
24	Rizzieri DA, Cooley S, Odenike O, Moonan L, Chow KH, Jackson K, Wang X, Brail L and Borthakur G: An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leuk Lymphoma. 57:1800–1806. 2016. View Article : Google Scholar : PubMed/NCBI
25	Dignam JD, Lebovitz RM and Roeder RG: Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1475–1489. 1983. View Article : Google Scholar : PubMed/NCBI
26	Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F, O'Halloran T, et al: GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Lett. 380:384–392. 2016. View Article : Google Scholar : PubMed/NCBI
27	Quintayo MA, Munro AF, Thomas J, Kunkler IH, Jack W, Kerr GR, Dixon JM, Chetty U and Bartlett JM: GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients. Breast Cancer Res Treat. 136:161–168. 2012. View Article : Google Scholar : PubMed/NCBI
28	Shin S, Wolgamott L, Tcherkezian J, Vallabhapurapu S, Yu Y, Roux PP and Yoon SO: Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene. 33:1690–1699. 2014. View Article : Google Scholar : PubMed/NCBI
29	Darrington RS, Campa VM, Walker MM, Bengoa-Vergniory N, Gorrono-Etxebarria I, Uysal-Onganer P, Kawano Y, Waxman J and Kypta RM: Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer. Int J Cancer. 131:E872–E883. 2012. View Article : Google Scholar : PubMed/NCBI
30	Rask K, Nilsson A, Brännström M, Carlsson P, Hellberg P, Janson PO, Hedin L and Sundfeldt K: Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer. 89:1298–1304. 2003. View Article : Google Scholar : PubMed/NCBI
31	Vincent EE, Elder DJ, O'Flaherty L, Pardo OE, Dzien P, Phillips L, Morgan C, Pawade J, May MT, Sohail M, et al: Glycogen synthase kinase 3 protein kinase activity is frequently elevated in human non-small cell lung carcinoma and supports tumour cell proliferation. PLoS One. 9:e1147252014. View Article : Google Scholar : PubMed/NCBI
32	Zeng J, Liu D, Qiu Z, Huang Y, Chen B, Wang L, Xu H, Huang N, Liu L and Li W: GSK3β overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cells. PLoS One. 9:e912312014. View Article : Google Scholar : PubMed/NCBI
33	Cho YJ, Yoon J, Ko YS, Kim SY, Cho SJ, Kim WH, Park JW, Youn HD, Kim JH and Lee BL: Glycogen synthase kinase-3β does not correlate with the expression and activity of β-catenin in gastric cancer. APMIS. 118:782–790. 2010. View Article : Google Scholar : PubMed/NCBI
34	Salim T, Sjölander A and Sand-Dejmek J: Nuclear expression of glycogen synthase kinase-3β and lack of membranous β-catenin is correlated with poor survival in colon cancer. Int J Cancer. 133:807–815. 2013. View Article : Google Scholar : PubMed/NCBI
35	Pal K, Cao Y, Gaisina IN, Bhattacharya S, Dutta SK, Wang E, Gunosewoyo H, Kozikowski AP, Billadeau DD and Mukhopadhyay D: Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer. Mol Cancer Ther. 13:285–296. 2014. View Article : Google Scholar : PubMed/NCBI
36	Carter YM, Kunnimalaiyaan S, Chen H, Gamblin TC and Kunnimalaiyaan M: Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther. 15:510–515. 2014. View Article : Google Scholar : PubMed/NCBI
37	Duffy DJ, Krstic A, Schwarzl T, Higgins DG and Kolch W: GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling. Mol Cancer Ther. 13:454–467. 2014. View Article : Google Scholar : PubMed/NCBI
38	Hilliard TS, Gaisina IN, Muehlbauer AG, Gaisin AM, Gallier F and Burdette JE: Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. Anticancer Drugs. 22:978–985. 2011.PubMed/NCBI
39	Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J and Fine HA: Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 68:6643–6651. 2008. View Article : Google Scholar : PubMed/NCBI
40	Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA and Chen H: Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther. 6:1151–1158. 2007. View Article : Google Scholar : PubMed/NCBI
41	Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB and Li B: Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate. 71:835–845. 2011. View Article : Google Scholar : PubMed/NCBI
42	Ugolkov A, Qiang W, Bondarenko G, Procissi D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H, O'Halloran T, et al: Combination treatment with the GSK-3 inhibitor 9-ING-41 and CCNU cures orthotopic chemoresistant glioblastoma in patient-derived xenograft models. Transl Oncol. 10:669–678. 2017. View Article : Google Scholar : PubMed/NCBI
43	Ugolkov AV, Bondarenko GI, Dubrovskyi O, Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ, Giles FJ and Mazar AP: 9-ING-41, a small molecule glycogen synthase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 29:717–724. 2018.PubMed/NCBI
44	Kim SW, Roh J and Park CS: Immunohistochemistry for pathologists: Protocols, pitfalls and tips. J Pathol Transl Med. 50:411–418. 2016. View Article : Google Scholar : PubMed/NCBI
45	Cheuk W and Chan JK: Subcellular localization of immunohistochemical signals: Knowledge of the ultrastructural or biologic features of the antigens helps predict the signal localization and proper interpretation of immunostains. Int J Surg Pathol. 12:185–206. 2004. View Article : Google Scholar : PubMed/NCBI